A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Cooper Todd M.; Cassar Jeannette; Eckroth Elena; Malvar Jemily; Sposto Richard; Gaynon Paul; Chang Bill H.; Gore Lia; August Keith; Pollard Jessica A.; DuBois Steven G.; Silverman Lewis B.; Oesterheld Javier; Gammon Guy; Magoon Daniel; Annesley Colleen; Brown Patrick A.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

【24h】

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

机译：Quizartinib的I阶段与化疗在复发儿童白血病中的研究：儿童白血病＆淋巴瘤（TACL）研究中的治疗进展

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia.

机译：目的：确定Quizartinib（AC220），有效和选择性类III受体酪氨酸激酶（RTK）FLT3抑制剂的安全和生物活性剂量，与复发急性白血病的儿童组合。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第16期|共9页
作者
Cooper Todd M.; Cassar Jeannette; Eckroth Elena; Malvar Jemily; Sposto Richard; Gaynon Paul; Chang Bill H.; Gore Lia; August Keith; Pollard Jessica A.; DuBois Steven G.; Silverman Lewis B.; Oesterheld Javier; Gammon Guy; Magoon Daniel; Annesley Colleen; Brown Patrick A.;
展开▼
作者单位

Seattle Childrens Hosp Canc &

Blood Disorders Ctr 4800 Sand Point Way NE M-S MB8-501 Seattle WA;

Childrens Hosp Los Angeles Childrens Ctr Canc &

Blood Dis Los Angeles CA 90027 USA;

Childrens Hosp Los Angeles Childrens Ctr Canc &

Blood Dis Los Angeles CA 90027 USA;

Childrens Hosp Los Angeles Childrens Ctr Canc &

Blood Dis Los Angeles CA 90027 USA;

Childrens Hosp Los Angeles Childrens Ctr Canc &

Blood Dis Los Angeles CA 90027 USA;

Childrens Hosp Los Angeles Childrens Ctr Canc &

Blood Dis Los Angeles CA 90027 USA;

Oregon Hlth &

Sci Univ Doernbecher Childrens Hosp Portland OR 97201 USA;

Childrens Hosp Colorado Aurora CO USA;

Childrens Mercy Hosp &

Clin Kansas City MO USA;

Maine Childrens Canc Program Scarborough ME USA;

Boston Childrens Hosp Dana Farber Canc Inst Boston MA USA;

Boston Childrens Hosp Dana Farber Canc Inst Boston MA USA;

Levine Childrens Hosp Charlotte NC USA;

Ambit Biosci Corp Clin Res &

Dev San Diego CA USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study [J] . Cooper Todd M., Cassar Jeannette, Eckroth Elena, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第16期

机译：Quizartinib的I阶段与化疗在复发儿童白血病中的研究：儿童白血病＆淋巴瘤（TACL）研究中的治疗进展
2. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. [J] . Messinger Y, Gaynon P, Raetz E, Pediatric blood & cancer . 2010,第2期

机译：硼替佐米联合化学疗法治疗儿童复发性儿童急性淋巴细胞白血病（ALL）的I期研究：儿童白血病（TACL）联合体治疗进展的报告。
3. A phase i study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium [J] . RaetzE.A., MorrisonD., Romanos-SirakisE., Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology . 2014,第6期

机译：EZN-3042的一项i期研究，一种新型的survivin信使核糖核酸（mRNA）拮抗剂，与化疗联合用于儿童复发性急性淋巴细胞白血病（ALL）：儿童白血病和淋巴瘤（TACL）的治疗进展报告财团
4. Serum Interleukin-12: A Possible Marker for the Immune Response in Childhood Leukemias and Lymphomas [C] . Y.A. Al -Tonbary, M.M. El-Ayouty, M.I. Fouda, European Haematology Association . 2002

机译：血清白细胞介素-12：儿童白血病和淋巴瘤中免疫应答的可能标记
5. Physiological Stress Reactivity in Childhood Leukemia and Lymphoma Patients and an Exploration of Neurological and Behavioural Characteristics Associated with Stress Regulation [D] . White, Gillian Elizabeth. 2020

机译：儿童白血病和淋巴瘤患者的生理胁迫反应性以及与应力调节相关的神经和行为特征的探索
6. A Phase I Study of EZN-3042 a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist Administered in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL): A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium [O] . Elizabeth A. Raetz, Debra Morrison, Eleny Romanos-Sirakis, -1

机译：新型生存蛋白信使核糖核酸（mRNA）拮抗剂EZN-3042的I期研究与化疗联合用于复发性急性淋巴细胞白血病（ALL）患儿：儿童白血病和淋巴瘤（TACL）的治疗进展报告财团
7. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium [O] . Yoav Messinger, Paul Gaynon, Elizabeth Raetz, 2010

机译：Ⅰ期博尔特佐米与复发儿童急性淋巴细胞白血病儿童联合化疗（全部）：儿童白血病（TACL）联盟的治疗进展报告

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

摘要

著录项

相似文献

相关主题

期刊订阅